Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Subbiah V, et al. Among authors: cabanillas me. J Clin Oncol. 2018 Jan 1;36(1):7-13. doi: 10.1200/JCO.2017.73.6785. Epub 2017 Oct 26. J Clin Oncol. 2018. PMID: 29072975 Free PMC article. Clinical Trial.
Sorafenib in metastatic thyroid cancer: a systematic review.
Thomas L, Lai SY, Dong W, Feng L, Dadu R, Regone RM, Cabanillas ME. Thomas L, et al. Among authors: cabanillas me. Oncologist. 2014 Mar;19(3):251-8. doi: 10.1634/theoncologist.2013-0362. Epub 2014 Feb 21. Oncologist. 2014. PMID: 24563075 Free PMC article. Review.
BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer.
Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R. Falchook GS, et al. Among authors: cabanillas me. Thyroid. 2015 Jan;25(1):71-7. doi: 10.1089/thy.2014.0123. Thyroid. 2015. PMID: 25285888 Free PMC article.
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.
Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME. Dadu R, et al. Among authors: cabanillas me. J Clin Endocrinol Metab. 2015 Jan;100(1):E77-81. doi: 10.1210/jc.2014-2246. J Clin Endocrinol Metab. 2015. PMID: 25353071 Free PMC article.
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister L, Funahashi Y, Ren M, O'Brien JP, Sherman SI. Schlumberger M, et al. Among authors: cabanillas me. Clin Cancer Res. 2016 Jan 1;22(1):44-53. doi: 10.1158/1078-0432.CCR-15-1127. Epub 2015 Aug 26. Clin Cancer Res. 2016. PMID: 26311725 Clinical Trial.
157 results